APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Progressive Supranuclear Palsy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Progressive Supranuclear Palsy Market Analysis and Forecast 2026-2032

31 December 2025199 pages

Choose your research edition.

Industry ResearchProgressive Supranuclear Palsy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Progressive Supranuclear Palsy Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Progressive Supranuclear Palsy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Progressive Supranuclear Palsy Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Progressive Supranuclear Palsy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Progressive Supranuclear Palsy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Progressive Supranuclear Palsy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Progressive Supranuclear Palsy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Progressive Supranuclear Palsy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Progressive Supranuclear Palsy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Progressive Supranuclear Palsy include Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc, Biogen Inc., Bristol Myers Squibb (BMS), AbbVie Inc., Acorda Therapeutics Inc., Teva Pharmaceutical Industries Ltd. and Cortice Biosciences, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Progressive Supranuclear Palsy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Progressive Supranuclear Palsy, also provides the revenue of main regions and countries. Of the upcoming market potential for Progressive Supranuclear Palsy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Progressive Supranuclear Palsy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Progressive Supranuclear Palsy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Progressive Supranuclear Palsy revenue, projected growth trends, production technology, application and end-user industry.

Progressive Supranuclear Palsy Segment by Company

Novartis AG

Merck & Co., Inc.

GlaxoSmithKline plc

Biogen Inc.

Bristol Myers Squibb (BMS)

AbbVie Inc.

Acorda Therapeutics Inc.

Teva Pharmaceutical Industries Ltd.

Cortice Biosciences, Inc.

Aton Pharma, Inc.

AlzProtect SAS

AB Science

Progressive Supranuclear Palsy Segment by Type

Late Stage

Clinical Trial

Early Stage

Others

Progressive Supranuclear Palsy Segment by Application

Clinics

Hospitals

Research Institutes

Others

Progressive Supranuclear Palsy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Progressive Supranuclear Palsy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Progressive Supranuclear Palsy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Progressive Supranuclear Palsy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Progressive Supranuclear Palsy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Progressive Supranuclear Palsy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Progressive Supranuclear Palsy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Progressive Supranuclear Palsy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Late Stage Major Player Table 3. Clinical Trial Major Player Table 4. Early Stage Major Player Table 5. Others Major Player Table 6. Global Progressive Supranuclear Palsy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Clinics Major Player Table 8. Hospitals Major Player Table 9. Research Institutes Major Player Table 10. Others Major Player Table 11. Progressive Supranuclear Palsy Industry Trends Table 12. Progressive Supranuclear Palsy Industry Drivers Table 13. Progressive Supranuclear Palsy Industry Opportunities and Challenges Table 14. Progressive Supranuclear Palsy Industry Restraints Table 15. Global Progressive Supranuclear Palsy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Progressive Supranuclear Palsy Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Progressive Supranuclear Palsy Market Share by Region (2021-2026) Table 18. Global Progressive Supranuclear Palsy Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Progressive Supranuclear Palsy Market Share by Region (2027-2032) Table 20. Global Progressive Supranuclear Palsy Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Progressive Supranuclear Palsy Revenue Market Share by Players (2021-2026) Table 22. Global Progressive Supranuclear Palsy Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Progressive Supranuclear Palsy Key Players Headquarters & Area Served Table 24. Global Progressive Supranuclear Palsy Players, Product Type & Application Table 25. Global Progressive Supranuclear Palsy Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Progressive Supranuclear Palsy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Progressive Supranuclear Palsy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Progressive Supranuclear Palsy Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Progressive Supranuclear Palsy Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Progressive Supranuclear Palsy Revenue Market Share by Type (2021-2026) Table 32. Global Progressive Supranuclear Palsy Revenue Market Share by Type (2027-2032) Table 33. Global Progressive Supranuclear Palsy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Progressive Supranuclear Palsy Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Progressive Supranuclear Palsy Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Progressive Supranuclear Palsy Revenue Market Share by Application (2021-2026) Table 37. Global Progressive Supranuclear Palsy Revenue Market Share by Application (2027-2032) Table 38. Novartis AG Company Information Table 39. Novartis AG Business Overview Table 40. Novartis AG Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Novartis AG Progressive Supranuclear Palsy Product Portfolio Table 42. Novartis AG Recent Development Table 43. Merck & Co., Inc. Company Information Table 44. Merck & Co., Inc. Business Overview Table 45. Merck & Co., Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Merck & Co., Inc. Progressive Supranuclear Palsy Product Portfolio Table 47. Merck & Co., Inc. Recent Development Table 48. GlaxoSmithKline plc Company Information Table 49. GlaxoSmithKline plc Business Overview Table 50. GlaxoSmithKline plc Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. GlaxoSmithKline plc Progressive Supranuclear Palsy Product Portfolio Table 52. GlaxoSmithKline plc Recent Development Table 53. Biogen Inc. Company Information Table 54. Biogen Inc. Business Overview Table 55. Biogen Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Biogen Inc. Progressive Supranuclear Palsy Product Portfolio Table 57. Biogen Inc. Recent Development Table 58. Bristol Myers Squibb (BMS) Company Information Table 59. Bristol Myers Squibb (BMS) Business Overview Table 60. Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Product Portfolio Table 62. Bristol Myers Squibb (BMS) Recent Development Table 63. AbbVie Inc. Company Information Table 64. AbbVie Inc. Business Overview Table 65. AbbVie Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. AbbVie Inc. Progressive Supranuclear Palsy Product Portfolio Table 67. AbbVie Inc. Recent Development Table 68. Acorda Therapeutics Inc. Company Information Table 69. Acorda Therapeutics Inc. Business Overview Table 70. Acorda Therapeutics Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Acorda Therapeutics Inc. Progressive Supranuclear Palsy Product Portfolio Table 72. Acorda Therapeutics Inc. Recent Development Table 73. Teva Pharmaceutical Industries Ltd. Company Information Table 74. Teva Pharmaceutical Industries Ltd. Business Overview Table 75. Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Product Portfolio Table 77. Teva Pharmaceutical Industries Ltd. Recent Development Table 78. Cortice Biosciences, Inc. Company Information Table 79. Cortice Biosciences, Inc. Business Overview Table 80. Cortice Biosciences, Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Cortice Biosciences, Inc. Progressive Supranuclear Palsy Product Portfolio Table 82. Cortice Biosciences, Inc. Recent Development Table 83. Aton Pharma, Inc. Company Information Table 84. Aton Pharma, Inc. Business Overview Table 85. Aton Pharma, Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Aton Pharma, Inc. Progressive Supranuclear Palsy Product Portfolio Table 87. Aton Pharma, Inc. Recent Development Table 88. AlzProtect SAS Company Information Table 89. AlzProtect SAS Business Overview Table 90. AlzProtect SAS Progressive Supranuclear Palsy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. AlzProtect SAS Progressive Supranuclear Palsy Product Portfolio Table 92. AlzProtect SAS Recent Development Table 93. AB Science Company Information Table 94. AB Science Business Overview Table 95. AB Science Progressive Supranuclear Palsy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. AB Science Progressive Supranuclear Palsy Product Portfolio Table 97. AB Science Recent Development Table 98. North America Progressive Supranuclear Palsy Revenue by Type (2021-2026) & (US$ Million) Table 99. North America Progressive Supranuclear Palsy Revenue by Type (2027-2032) & (US$ Million) Table 100. North America Progressive Supranuclear Palsy Revenue by Application (2021-2026) & (US$ Million) Table 101. North America Progressive Supranuclear Palsy Revenue by Application (2027-2032) & (US$ Million) Table 102. North America Progressive Supranuclear Palsy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. North America Progressive Supranuclear Palsy Revenue by Country (2021-2026) & (US$ Million) Table 104. North America Progressive Supranuclear Palsy Revenue by Country (US$ Million) & (2027-2032) Table 105. Europe Progressive Supranuclear Palsy Revenue by Type (2021-2026) & (US$ Million) Table 106. Europe Progressive Supranuclear Palsy Revenue by Type (2027-2032) & (US$ Million) Table 107. Europe Progressive Supranuclear Palsy Revenue by Application (2021-2026) & (US$ Million) Table 108. Europe Progressive Supranuclear Palsy Revenue by Application (2027-2032) & (US$ Million) Table 109. Europe Progressive Supranuclear Palsy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Europe Progressive Supranuclear Palsy Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Progressive Supranuclear Palsy Revenue by Country (US$ Million) & (2027-2032) Table 112. China Progressive Supranuclear Palsy Revenue by Type (2021-2026) & (US$ Million) Table 113. China Progressive Supranuclear Palsy Revenue by Type (2027-2032) & (US$ Million) Table 114. China Progressive Supranuclear Palsy Revenue by Application (2021-2026) & (US$ Million) Table 115. China Progressive Supranuclear Palsy Revenue by Application (2027-2032) & (US$ Million) Table 116. Asia Progressive Supranuclear Palsy Revenue by Type (2021-2026) & (US$ Million) Table 117. Asia Progressive Supranuclear Palsy Revenue by Type (2027-2032) & (US$ Million) Table 118. Asia Progressive Supranuclear Palsy Revenue by Application (2021-2026) & (US$ Million) Table 119. Asia Progressive Supranuclear Palsy Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Progressive Supranuclear Palsy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Asia Progressive Supranuclear Palsy Revenue by Region (US$ Million) & (2021-2026) Table 122. Asia Progressive Supranuclear Palsy Revenue by Region (US$ Million) & (2027-2032) Table 123. SAMEA Progressive Supranuclear Palsy Revenue by Type (2021-2026) & (US$ Million) Table 124. SAMEA Progressive Supranuclear Palsy Revenue by Type (2027-2032) & (US$ Million) Table 125. SAMEA Progressive Supranuclear Palsy Revenue by Application (2021-2026) & (US$ Million) Table 126. SAMEA Progressive Supranuclear Palsy Revenue by Application (2027-2032) & (US$ Million) Table 127. SAMEA Progressive Supranuclear Palsy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. SAMEA Progressive Supranuclear Palsy Revenue by Country (2021-2026) & (US$ Million) Table 129. SAMEA Progressive Supranuclear Palsy Revenue by Country (US$ Million) & (2027-2032) Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Progressive Supranuclear Palsy Image Figure 2. Global Progressive Supranuclear Palsy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Progressive Supranuclear Palsy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Late Stage Image Figure 5. Clinical Trial Image Figure 6. Early Stage Image Figure 7. Others Image Figure 8. Global Progressive Supranuclear Palsy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Progressive Supranuclear Palsy Market Size Share 2021 VS 2025 VS 2032 Figure 10. Clinics Image Figure 11. Hospitals Image Figure 12. Research Institutes Image Figure 13. Others Image Figure 14. Global Progressive Supranuclear Palsy Market Size (US$ Million) & (2021-2032) Figure 15. Global Progressive Supranuclear Palsy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Progressive Supranuclear Palsy Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Progressive Supranuclear Palsy Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Progressive Supranuclear Palsy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Progressive Supranuclear Palsy Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Progressive Supranuclear Palsy Revenue Market Share by Type (2021-2032) Figure 22. Global Progressive Supranuclear Palsy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Progressive Supranuclear Palsy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Progressive Supranuclear Palsy Revenue Market Share by Application (2021-2032) Figure 25. North America Progressive Supranuclear Palsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Progressive Supranuclear Palsy Revenue Share by Type (2021-2032) Figure 27. North America Progressive Supranuclear Palsy Revenue Share by Application (2021-2032) Figure 28. North America Progressive Supranuclear Palsy Revenue Share by Country (2021-2032) Figure 29. United States Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Progressive Supranuclear Palsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Progressive Supranuclear Palsy Revenue Share by Type (2021-2032) Figure 34. Europe Progressive Supranuclear Palsy Revenue Share by Application (2021-2032) Figure 35. Europe Progressive Supranuclear Palsy Revenue Share by Country (2021-2032) Figure 36. Germany Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Progressive Supranuclear Palsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Progressive Supranuclear Palsy Revenue Share by Type (2021-2032) Figure 46. China Progressive Supranuclear Palsy Revenue Share by Application (2021-2032) Figure 47. Asia Progressive Supranuclear Palsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Progressive Supranuclear Palsy Revenue Share by Type (2021-2032) Figure 49. Asia Progressive Supranuclear Palsy Revenue Share by Application (2021-2032) Figure 50. Asia Progressive Supranuclear Palsy Revenue Share by Region (2021-2032) Figure 51. Japan Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Progressive Supranuclear Palsy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Progressive Supranuclear Palsy Revenue Share by Type (2021-2032) Figure 59. SAMEA Progressive Supranuclear Palsy Revenue Share by Application (2021-2032) Figure 60. SAMEA Progressive Supranuclear Palsy Revenue Share by Country (2021-2032) Figure 61. Brazil Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Progressive Supranuclear Palsy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Late Stage
  • Clinical Trial
  • Early Stage
  • Others
Applications
  • Clinics
  • Hospitals
  • Research Institutes
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Biogen Inc.
  • Bristol Myers Squibb (BMS)
  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cortice Biosciences, Inc.
  • Aton Pharma, Inc.
  • AlzProtect SAS
  • AB Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Progressive Supranuclear Palsy Market by Type
  3. 1.2.1 Global Progressive Supranuclear Palsy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Late Stage
  5. 1.2.3 Clinical Trial
  6. 1.2.4 Early Stage
  7. 1.2.5 Others
  8. 1.3 Progressive Supranuclear Palsy Market by Application
  9. 1.3.1 Global Progressive Supranuclear Palsy Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Clinics
  11. 1.3.3 Hospitals
  12. 1.3.4 Research Institutes
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Progressive Supranuclear Palsy Market Dynamics
  1. 2.1 Progressive Supranuclear Palsy Industry Trends
  2. 2.2 Progressive Supranuclear Palsy Industry Drivers
  3. 2.3 Progressive Supranuclear Palsy Industry Opportunities and Challenges
  4. 2.4 Progressive Supranuclear Palsy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Progressive Supranuclear Palsy Market Perspective (2021-2032)
  2. 3.2 Global Progressive Supranuclear Palsy Growth Trends by Region
  3. 3.2.1 Global Progressive Supranuclear Palsy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Progressive Supranuclear Palsy Market Size by Region (2021-2026)
  5. 3.2.3 Global Progressive Supranuclear Palsy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Progressive Supranuclear Palsy Revenue by Players
  2. 4.1.1 Global Progressive Supranuclear Palsy Revenue by Players (2021-2026)
  3. 4.1.2 Global Progressive Supranuclear Palsy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Progressive Supranuclear Palsy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Progressive Supranuclear Palsy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Progressive Supranuclear Palsy Key Players Headquarters & Area Served
  7. 4.4 Global Progressive Supranuclear Palsy Players, Product Type & Application
  8. 4.5 Global Progressive Supranuclear Palsy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Progressive Supranuclear Palsy Market CR5 and HHI
  11. 4.6.3 2025 Progressive Supranuclear Palsy Tier 1, Tier 2, and Tier 3
5 Progressive Supranuclear Palsy Market Size by Type
  1. 5.1 Global Progressive Supranuclear Palsy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Progressive Supranuclear Palsy Revenue by Type (2021-2032)
  3. 5.3 Global Progressive Supranuclear Palsy Revenue Market Share by Type (2021-2032)
6 Progressive Supranuclear Palsy Market Size by Application
  1. 6.1 Global Progressive Supranuclear Palsy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Progressive Supranuclear Palsy Revenue by Application (2021-2032)
  3. 6.3 Global Progressive Supranuclear Palsy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Progressive Supranuclear Palsy Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Merck & Co., Inc.
  8. 7.2.1 Merck & Co., Inc. Company Information
  9. 7.2.2 Merck & Co., Inc. Business Overview
  10. 7.2.3 Merck & Co., Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co., Inc. Progressive Supranuclear Palsy Product Portfolio
  12. 7.2.5 Merck & Co., Inc. Recent Developments
  13. 7.3 GlaxoSmithKline plc
  14. 7.3.1 GlaxoSmithKline plc Company Information
  15. 7.3.2 GlaxoSmithKline plc Business Overview
  16. 7.3.3 GlaxoSmithKline plc Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline plc Progressive Supranuclear Palsy Product Portfolio
  18. 7.3.5 GlaxoSmithKline plc Recent Developments
  19. 7.4 Biogen Inc.
  20. 7.4.1 Biogen Inc. Company Information
  21. 7.4.2 Biogen Inc. Business Overview
  22. 7.4.3 Biogen Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Biogen Inc. Progressive Supranuclear Palsy Product Portfolio
  24. 7.4.5 Biogen Inc. Recent Developments
  25. 7.5 Bristol Myers Squibb (BMS)
  26. 7.5.1 Bristol Myers Squibb (BMS) Company Information
  27. 7.5.2 Bristol Myers Squibb (BMS) Business Overview
  28. 7.5.3 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Product Portfolio
  30. 7.5.5 Bristol Myers Squibb (BMS) Recent Developments
  31. 7.6 AbbVie Inc.
  32. 7.6.1 AbbVie Inc. Company Information
  33. 7.6.2 AbbVie Inc. Business Overview
  34. 7.6.3 AbbVie Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie Inc. Progressive Supranuclear Palsy Product Portfolio
  36. 7.6.5 AbbVie Inc. Recent Developments
  37. 7.7 Acorda Therapeutics Inc.
  38. 7.7.1 Acorda Therapeutics Inc. Company Information
  39. 7.7.2 Acorda Therapeutics Inc. Business Overview
  40. 7.7.3 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Product Portfolio
  42. 7.7.5 Acorda Therapeutics Inc. Recent Developments
  43. 7.8 Teva Pharmaceutical Industries Ltd.
  44. 7.8.1 Teva Pharmaceutical Industries Ltd. Company Information
  45. 7.8.2 Teva Pharmaceutical Industries Ltd. Business Overview
  46. 7.8.3 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Product Portfolio
  48. 7.8.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  49. 7.9 Cortice Biosciences, Inc.
  50. 7.9.1 Cortice Biosciences, Inc. Company Information
  51. 7.9.2 Cortice Biosciences, Inc. Business Overview
  52. 7.9.3 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Product Portfolio
  54. 7.9.5 Cortice Biosciences, Inc. Recent Developments
  55. 7.10 Aton Pharma, Inc.
  56. 7.10.1 Aton Pharma, Inc. Company Information
  57. 7.10.2 Aton Pharma, Inc. Business Overview
  58. 7.10.3 Aton Pharma, Inc. Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Aton Pharma, Inc. Progressive Supranuclear Palsy Product Portfolio
  60. 7.10.5 Aton Pharma, Inc. Recent Developments
  61. 7.11 AlzProtect SAS
  62. 7.11.1 AlzProtect SAS Company Information
  63. 7.11.2 AlzProtect SAS Business Overview
  64. 7.11.3 AlzProtect SAS Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 AlzProtect SAS Progressive Supranuclear Palsy Product Portfolio
  66. 7.11.5 AlzProtect SAS Recent Developments
  67. 7.12 AB Science
  68. 7.12.1 AB Science Company Information
  69. 7.12.2 AB Science Business Overview
  70. 7.12.3 AB Science Progressive Supranuclear Palsy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AB Science Progressive Supranuclear Palsy Product Portfolio
  72. 7.12.5 AB Science Recent Developments
8 North America
  1. 8.1 North America Progressive Supranuclear Palsy Revenue (2021-2032)
  2. 8.2 North America Progressive Supranuclear Palsy Revenue by Type (2021-2032)
  3. 8.2.1 North America Progressive Supranuclear Palsy Revenue by Type (2021-2026)
  4. 8.2.2 North America Progressive Supranuclear Palsy Revenue by Type (2027-2032)
  5. 8.3 North America Progressive Supranuclear Palsy Revenue Share by Type (2021-2032)
  6. 8.4 North America Progressive Supranuclear Palsy Revenue by Application (2021-2032)
  7. 8.4.1 North America Progressive Supranuclear Palsy Revenue by Application (2021-2026)
  8. 8.4.2 North America Progressive Supranuclear Palsy Revenue by Application (2027-2032)
  9. 8.5 North America Progressive Supranuclear Palsy Revenue Share by Application (2021-2032)
  10. 8.6 North America Progressive Supranuclear Palsy Revenue by Country
  11. 8.6.1 North America Progressive Supranuclear Palsy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Progressive Supranuclear Palsy Revenue by Country (2021-2026)
  13. 8.6.3 North America Progressive Supranuclear Palsy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Progressive Supranuclear Palsy Revenue (2021-2032)
  2. 9.2 Europe Progressive Supranuclear Palsy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Progressive Supranuclear Palsy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Progressive Supranuclear Palsy Revenue by Type (2027-2032)
  5. 9.3 Europe Progressive Supranuclear Palsy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Progressive Supranuclear Palsy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Progressive Supranuclear Palsy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Progressive Supranuclear Palsy Revenue by Application (2027-2032)
  9. 9.5 Europe Progressive Supranuclear Palsy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Progressive Supranuclear Palsy Revenue by Country
  11. 9.6.1 Europe Progressive Supranuclear Palsy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Progressive Supranuclear Palsy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Progressive Supranuclear Palsy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Progressive Supranuclear Palsy Revenue (2021-2032)
  2. 10.2 China Progressive Supranuclear Palsy Revenue by Type (2021-2032)
  3. 10.2.1 China Progressive Supranuclear Palsy Revenue by Type (2021-2026)
  4. 10.2.2 China Progressive Supranuclear Palsy Revenue by Type (2027-2032)
  5. 10.3 China Progressive Supranuclear Palsy Revenue Share by Type (2021-2032)
  6. 10.4 China Progressive Supranuclear Palsy Revenue by Application (2021-2032)
  7. 10.4.1 China Progressive Supranuclear Palsy Revenue by Application (2021-2026)
  8. 10.4.2 China Progressive Supranuclear Palsy Revenue by Application (2027-2032)
  9. 10.5 China Progressive Supranuclear Palsy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Progressive Supranuclear Palsy Revenue (2021-2032)
  2. 11.2 Asia Progressive Supranuclear Palsy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Progressive Supranuclear Palsy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Progressive Supranuclear Palsy Revenue by Type (2027-2032)
  5. 11.3 Asia Progressive Supranuclear Palsy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Progressive Supranuclear Palsy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Progressive Supranuclear Palsy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Progressive Supranuclear Palsy Revenue by Application (2027-2032)
  9. 11.5 Asia Progressive Supranuclear Palsy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Progressive Supranuclear Palsy Revenue by Country
  11. 11.6.1 Asia Progressive Supranuclear Palsy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Progressive Supranuclear Palsy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Progressive Supranuclear Palsy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Progressive Supranuclear Palsy Revenue (2021-2032)
  2. 12.2 SAMEA Progressive Supranuclear Palsy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Progressive Supranuclear Palsy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Progressive Supranuclear Palsy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Progressive Supranuclear Palsy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Progressive Supranuclear Palsy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Progressive Supranuclear Palsy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Progressive Supranuclear Palsy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Progressive Supranuclear Palsy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Progressive Supranuclear Palsy Revenue by Country
  11. 12.6.1 SAMEA Progressive Supranuclear Palsy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Progressive Supranuclear Palsy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Progressive Supranuclear Palsy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst